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Purpose: To report the clinical features and identification of two novel mutations in two Chinese pedigrees with autosomal
dominant optic atrophy (ADOA).
Methods: Two families (F1 and F2) including ten affected members and nine unaffected family individuals were examined
clinically. After informed consent was obtained, peripheral blood samples of all the participants were obtained, and
genomic DNA was extracted. Linkage analysis was performed with two microsatellite markers around the OPA1 gene
(D3S2305 and D3S3562) in family F1. The coding region (exon 1–28), including intron-exon boundary of the OPA1 gene,
were screened in the 2 families by polymerase chain reaction (PCR) and direct DNA sequencing. Whenever substitutions
were identified in a patient, single strand conformation polymorphism (SSCP) analysis was performed on all available
family members and 100 normal controls. To characterize a splicing site mutation, RT–PCR of total RNA of leukocytes
obtained from three patients and seven unaffected individuals of family F1 was performed with the specific primers.
Results: The affected individuals all presented with bilateral visual failure and temporal or total pallor of the optic discs.
Genotyping of family F1 revealed the linkage to the OPA1 gene on 3q28–29. After sequencing of OPA1 gene, a novel
heterozygous splicing site mutation c.985 −2A>G in intron 9 was found in family F1. RT–PCR result showed the skipping
of the exon 10 in the mutant transcript, which results in loss of 27 amino acids in the OPA1 protein. A novel heterozygous
nonsense mutation c.2197C>T(p.R733X)was detected in family F2.
Conclusions: Our findings expand the spectrum of OPA1 mutations and further established the role of OPA1 gene in
Chinese patients with ADOA.
Autosomal  dominant  optic  atrophy  (ADOA,  OMIM
165500),  also  called  Kjer  type  optic  atrophy,  is  the  most
frequent form of inherited optic neuropathy with a prevalence
of  between  1:10,000  and  1:50,000  [1,2].  It  is  a  disorder
characterized  by  slowly  progressive  visual  loss  usually
starting  in  childhood,  color  vision  defects,  centrocecal
scotomas, and temporal optic nerve pallor [3]. The results of
histopathological examinations of affected donor eyes suggest
that the fundamental pathology is degeneration of the retinal
ganglion cells and loss of myelin and nerve tissue within the
optic  nerve  [4].  ADOA  is  genetic  heterogeneous,  and  4
chromosome loci for the ADOA have been mapped [5–8]. Of
the 4 loci, only OPA1 gene (3q28–29) [5] and OPA3 gene
(19q13) [7] have been identified. Mutations in the OPA1gene
account for the majority of cases of ADOA [9,10], while
mutations in the OPA3 gene cause ADOA with cataract [7].
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The OPA1 gene on chromosome 3q28–29 consists of 28
coding exons and encodes a 960 amino acid polypeptide [9,
10]. Due to alternative splicing of exon 4, 4b, 5b, the OPA1
gene has 8 mRNA splicing isoforms with different expression
in different tissues. In human retina and brain, isoform 1
(missing exon 4b and 5b) and isoform 4 (missing exon 4 and
4b) have been shown to have the predominate expression
[11]. OPA1 protein is a dynamin-related GTPase targeted to
mitochondria,  which  locates  mostly  on  the  mitochondrial
inner  membrane  [12,13].  OPA1  consists  of  5  domains:
mitochondrial target signal (MTS), N-terminal (N-terminal)
coiled-coil domain, GTPase domain, dynamin central region,
and C-terminal (C-terminal) coiled-coil domain [13]. OPA1
is thought to be involved in multiple functions, the key role
being  the  regulation  of  mitochondrial  dynamics,  the
maintenance of structural integrity of the cristae [12–14], and
regulation of the apoptotic process through the control of
cytochrome C redistribution [12–14].
To date, more than 100 mutations have been reported in
the OPA1 gene and most of them are localized to the N-
terminal leader sequence (exon 1–2), the GTPase domain
(exon 8–16), and C-terminal coiled-coil region (exon 27–28)
[9–11,15–24].
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2451In this study, we performed a mutation screening of the
OPA1 gene in two Chinese families affected with ADOA and
identified two novel mutations.
METHODS
Patients and DNA samples collection: This study was granted
approval by the Beijing Tongren Hospital Joint Committee on
Clinical  Investigation  and  conformed  to  the  tenets  of  the
Declaration of Helsinki. After informed consent was obtained,
each participant (two probands were examined in the Beijing
TongRen  Hospital,  the  other  participants,  including  14
individuals of family 1 and 3 members in family 2, were
examined  in  their  local  town  by  Dr.  Li  and  Dr.Tong)
underwent  clinical  examinations  including  best-corrected
visual  acuity  using  E  decimal  charts,  slit-lamp,  and
ophthalmoscope. Two probands of the families underwent
visual field, pattern visual evoked potential (P-VEP), and
color discrimination test. ADOA was diagnosed based on the
clinical  and  family  history,  the  bilateral  visual  loss,  and
temporal pallor of optic discs. Peripheral blood was obtained
by venipuncture in heparinized collecting tube and kept in
4 °C less than one week, and genomic DNA was extracted
according to standard phenol protocols.
Linkage  analysis:  Genotyping  and  linkage  analysis  were
performed  with  two  microsatellite  markers  D3S2305  and
D3S3562  around  the  OPA1  gene  in  family  F1.  The  fine
mapping  primer  sequences  were  obtained  from  the  GDB
Human Genome Database. Pedigree and haplotype map were
constructed using Cyrillic V. 2.0 software.
Mutation screening of the OPA1 gene: Mutation screening
was performed in the two families using direct DNA sequence
analysis. Primers of 1–28 exons and exon-intron boundaries
of the OPA1 gene were designed by the Primer3 program.
Details of the primer sequences are shown in Table 1. For
direct sequencing, PCR products were purified (Shenneng
Bocai PCR purification kit; Shenneng, Shanghai, China). The
purified PCR products were sequenced using an automatic
fluorescence  DNA  sequencer  (ABI,  Prism  373A;  Perkin
Elmer,  Foster  City,  CA),  according  to  the  manufacturer’s
instructions. Nucleotide sequences were compared with the
published  DNA  sequence  of  OPA1  isoform  1  (GenBank
accession  number  NM_015560.1)  using  DNAssit  Version
1.0. For OPA1 gene cDNA numbering +1 corresponds to A
in the ATG translation initiation codon of OPA1 isoform 1.
Single strand conformation polymorphism: To confirm the
variations  found  in  the  sequencing,  we  conducted  single
strand conformation polymorphism (SSCP) analysis in all
available family members and 100 normal controls. Amplified
DNA was mixed with an equal volume formamide buffer that
contained  95%  formamide,  10  mM  EDTA,  0.1%
bromophenol  blue,  and  0.1%  xylene  cyanol.  Denatured
samples  were  electrophoresed  on  a  16%  non-denaturing
polyacrylamide gel (acrylamide:bisacrylamide=49:1) in Tris-
borate-EDTA buffer (89 mM Tris base, 2 mM EDTA, and
TABLE 1. PCR PRIMERS USED IN THIS STUDY
Primer Forward (5′-3′) Reverse(5′-3′)
Exon1 CCACTTCCTGGGTCATTCC AGAATTAACGGGGCCAGATT
Exon 2 CCCTCTCTGATCTTTCTTCCAT TAATTGGAAAACCAGGAGGA
Exon 3 TATTTGGCATGCAGAGCATC TCTCTTTCCTCGAGATGACCA
Exon 4 GGGTTGTCATGAGGATTAAACAA CATGTATTTTTCCTCCATGGTTC
Exon 5 AAAGGCGATTTGATTCTTTGAA TCTTTCAAGACTACCTACATGAACAA
Exon 6 AAAAATTTAACTTGCTGTACATTCTG CACCTTCCAAATTTTGCTCTG
Exon 7 TCAAGATTTTGGAAGATTTTAATTTAG CACACAACGTTAAGCGGTAAAA
Exon 8 CCGTTTTAGTTTTTACGATGAAGA TTTTTGCTAGTTGGCAAGTTCA
Exon 9 AAAAACTCAGAGCAGCATTACAAA CCTAAGGAACCTCACTGAGACG
Exon 10,11 CATACGGGCTGTGGGAATTA CCATAAAACGTCACTGAAATGAA
Exon 12,13 GAATTTTTAGAATACATTTCACCAAAA TGGATTGCTAAAGAAGAAAACAT
Exon 14 GACACAGGGGTATAATTTGTACTGA TTCTCGCAACAAAGAATTTGA
Exon 15,16 TTTTGCTTTCTAAATTGTATATTACGC TGAAAACAGTTCAATTTAAGCTACTC
Exon 17 CATTCGCAGACTTGGTGGTA TGTCTTAATTTGCTTGCTTCTTT
Exon 18 CCACTTTAACCACTACATCTGGAA AGCTTATCAGATTTTTCTCTCAACA
Exon 19 TCTGAAAATCATGACAGGGTAAA CAAGGCAACAATAAATCACTGC
Exon 20 TGATACTTCAGTCAAGCTGTTTTT CAGCTCCTACTCCCTTCAGA
Exon 21 TTTTTCATGTTAACCATTGAAGTATG GAGGCTGATACCCCAGTATACAA
Exon 22 TTTTTCCATATTTACTAAGCTGTCAA TCACCACTGTGAACTCAGAACTC
Exon 23 TTCCTTTATTTCAACTGCCTTCA AATGCCTGAATTAAAATGAACAA
Exon 24 TCAAGCACCAAATTATGAACCA GCAGATTCCTGCTTCTCAGC
Exon 25 TGTACAACTTCTCAGTGTGGTTGA GCATATTTTGACAACTGTTGCTT
Exon 26 AAGCTTAGGACATATCTACTGGTTCT TGGGAAGTATTTTGGCATCC
Exon 27 TCTTTATTCATTTATAAAAACGATGC AAATGGGAAAGGTGGAAAGG
Exon 28 CCTCCTGATTTGTGATACCTTTG CAAGCAGGATGTAAATGAAGCA
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245289 mM Boric acid, pH 8.0) for 12–16 h at 300 v and 4 °C
before gels were silver-stained and analyzed [25].
Reverse  transcription-polymerase  chain  reaction:
Lymphocytes from peripheral blood were isolated from the 3
patients and 7 unaffected individuals of family F1. Total RNA
was extracted with TRIZOL Reagent (Invitrogen, Carlsbad,
CA). Reverse transcription of isolated RNA was performed
using the First-Strand cDNA Synthesis Kit (Toyobo, Osaka,
Japan) with random primers. The transcribed OPA1 fragment
from exon 9 to exon 11 was amplified using the following
primer pair: forward, 5′- TGG AGA TCA GAG TGC TGG
AA-3′; and reverse, 5′- CTC AGG GCT AAC GGT ACA
GC-3′. RT–PCR products were separated on a 1% agarose gel
and sequenced.
RESULTS
Clinical findings: We have identified two unrelated Chinese
families consisting of 10 patients and 9 unaffected relatives
diagnosed with optic atrophy. The inheritance pattern in the
two  families  was  autosomal  dominant  (Figure  1).  All  the
patients had experienced bilateral vision acuity impairment at
their childhood. The ophthalmoscope demonstrated bilateral
temporal  or  total  pallor  of  the  optic  discs  (Figure  2).
Pseudoisochromatic  plates  test  showed  red-green  color
weakness. The two probands had P-VEP recordings with the
decreased amplitude and prolonged latency of P100 wave.
Octopus visual field of the proband in family F2 showed
bilateral  central  scotoma.  Detailed  clinical  information  of
each family’s affected member is summarized in Table 2.
None of the participants from either family presented with
hearing loss, cataract, ptosis, or ophthalmoplegia.
Genotyping results: Family F1 was genotyped with two short
tandem repeat polymorphism (STRP) markers located around
the OPA1 gene in the 3q28–29 region. The marker results for
D3S2305 and D3S3562 were fully informative for linkage.
There was no affected recombinant for either of the 2 markers
(Figure 1). Although a meiotic breakpoint was observed in an
unaffected family member (III:7), the marker D3S2305 was
very close to the OPA1 locus, whereas marker D3S3562 was
further telomeric and did not comprise any part of the OPA1
gene. However, one clinical unaffected individual (III: 2)
carried the affected haplotype.
Mutation  analysis:  After  sequencing  the  OPA1  gene,  we
identified two novel heterozygous mutations: a splicing site
mutation c.985 −2A>G in family F1 and a nonsense mutation
Figure 1. Family structure and haplotype analysis of the two Chinese families with ADOA. Pedigree of the two families with autosomal
dominant optic atrophy (ADOA) and haplotype analysis of the family F1 showed segregation two microsatellite markers on chromosome 3
listed in descending order from the centromeric end. Squares indicate males; circles indicate females; slashed symbols indicate deceased; solid
symbols indicate affected; open symbols indicate unaffected; and arrow symbol indicates proband.
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analysis,  we  found  that  these  heterozygous  mutations
cosegregated  with  all  affected  members  and  the  affected
haplotype carrier, but we did not detect them in 100 unrelated
normal controls.
To test whether the splice-site mutation lead to a defective
mRNA, we performed an RT–PCR assay to amplify OPA1
mRNA from total RNA isolated from peripheral blood of the
3 patients and 7 normal individuals. Two fragments (about
270 bp and 189 bp) were obtained from the patients, while
only 1 fragment (about 270 bp) was obtained from the normal
controls (Figure 4). The results of sequencing revealed that
the  270  bp  fragment  was  normal;  however,  the  189  bp
fragment showed the skipping of exon 10 (Figure 4).
DISCUSSION
In  this  study,  we  examined  two  Chinese  families  with
clinically diagnosed ADOA and screened the OPA1 gene. We
identified a novel heterozygous splicing site mutation c.985–
Figure 3. Direct sequencing analysis of the coding region of the
OPA1  gene.  A.  Sequence  shows  the  heterozygous  splicing  site
mutation  c.985–2A>G;  B:  Sequence  shows  the  heterozygous
nonsense mutation c.2197C>T (p. R733X). The 2 sequences given
are in sense direction.
Figure 4. RT–PCR and direct sequencing analysis for the splice site
mutation c.985–2A>G. A: Ethidium bromide-agarose gel was loaded
with RT–PCR products generated from leukocytes of total RNA of
three affected members (two bands) and seven unaffected individuals
(one band) of family F1. B and C: The sequence chromatograms of
the two bands from the patient’s RT–PCR products; B: The mutant
transcript sequence with the skipping exon 10. C: The corresponding
normal transcript sequence between exon 9 and exon 11.
Figure 2. Fundus appearance of a patient with autosomal dominant optic atrophy (ADOA). Fundus of proband of family F2 showed bilateral
temporal pallor of optic discs.
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24542A>G  and  a  novel  heterozygous  nonsense  mutation  c.
2197C>T (p.R733X). The 2 novel mutations cosegregated
with the disease phenotype and were not detected in 100
normal controls.
To date, more than 100 OPA1 gene mutations have been
reported  [9–11,15–24];  however,  only  2  mutations  were
reported in Chinese patients. The 2 mutations, a missense
p.G401D and a small deletion p. D950CfsX4, are associated
with a complex clinical phenotype characterized by ADOA
with sensorineural deafness [21,22]. Therefore, the current
study is the first report of mutations causing isolate ADOA in
Chinese families. Among the mutations reported, more than
20% of them are splice site mutations, which are presumed to
result  in  the  in-frame  skipping  of  exons  or  premature
termination  of  OPA1  translation.  The  novel  splice-site
mutation c.985–2A>G detected in family F1 causes an in-
frame skipping of exon 10, which encodes 27 amino acids in
the  highly  conserved  GTPase  domain  of  OPA1  protein.
Delettre et al. reported a recurrent mutation c.985–1G>A,
which has a similar consequence [9,11]. This may suggest that
the segment encoded by the exon 10 is critical for the GTPase
activity of OPA1, and the exon 10 splice acceptor site may be
a mutation hot spot.
In our review of the literature, we found ADOA displays
great variability in phenotypic expression. It was originally
thought that penetrance was almost complete (98%) [16].
However, the subsequent molecular analysis revealed that the
disease  penetrance  is  much  lower.  Revised  estimates  of
penetrance have varied between 43% and 62% for different
OPA1 mutation [16]. Previously, only visual acuity and optic
disc  appearance  were  used  to  classify  a  mutation  carrier
penetrant [16]. Cohn et al. extended the clinical parameters to
include color vision and visual field assessment, and observed
that the overall penetrance for OPA1 mutations in the large
Australian  ADOA  pedigrees  was  82.5%  [23].  Using  this
clinical  standard,  they  recalculated  the  penetrance  of  2
families harboring c.2708del (TTAG) mutation previously
reported by Toomes et al. [16]. The recalculated penetrance
of the two families was 66% and 67% [23], which was higher
than the original 43% and 62% [16]. In the current study, one
clinically  unaffected  member  of  family  F1  carried  the
mutation  c.985–2A>G;  he  was  also  found  to  harbor  the
affected haplotype. The penetrance of ADOA for family F1
was 87.5% (7/8). The limitation of the study was that only
visual acuity and optic disc appearances were used to classify
the mutation carrier penetrant.
TABLE 2. CLINICAL FEATURES OF FAMILY MEMBERS IN THE TWO FAMILIES
Family
number
Pedigree
number Gender Age
Best corrected
Visual acuity OD
Best corrected
Visual acuity OS
Disc
appearance
F1 II:1 M 60 0.02 0.02 A
  II:2 F 56 1 1 N
  III:1 M 30 1 1 N
  III:2 M 29 1 1 N
  III:3 F 36 0.4 0.4 T
  II:4 F 53 0.02 0.02 A
  II:3 M 63 NLP* 0.8 N
  III:4 M 35 0.3 0.7 T
  III:5 F 30 1 1 N
  IV:1 F 5 0.2 0.2 T
  III:6 F 31 0.8 0.8 N
  II:6 F 51 0.04 0.02 A
  II:5 M 52 1 0.8 N
  III:7 M 20 1 1 N
  III:8 F 28 0.6 0.6 T
F2 I:1 M 46 0.1 0.1 T
  I:2 F 45 1 1 N
  II:1 M 21 0.1 0.1 T
  II:2 F 19 0.2 0.2 T
Abbreviations: male (M), female (F), total optic disc pallor (A), temporal optic disc pallor (T), normal (N), and no light perception
(NLP).  The asterisk indicates the eyeball had atrophied due to a corneal penetrating trauma. Clinical features of all participants
from the two families with ADOA were summarized in this table.
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detected  in  family  F2  presumably  caused  premature
termination of the OPA1 translation. The predicted effect of
this mutation would be a truncated protein lacking the 227
amino acids, accounting for loss of 26.6% of OPA1, including
the part of central dynamin domain and total coiled-coil region
at  the  C-terminus.  As  the  premature  stop  codons  are  not
located in the last exon of the OPA1 gene, there is a possibility
that  nonsense-mediated  mRNA  decay  (NMD)  might  be
involved  in  the  abnormal  RNAs  processing.  NMD  is  a
widespread cellular process that proofreads nascent mRNA
transcripts and destroys those that bear premature termination
codons before they are actually translated in truncated and
potentially harmful proteins [26]. In a recent study, Schimpf
et  al.  demonstrated  that  the  majority  of  nonsense  OPA1
mutations underwent NMD. Using pyrosequencing of an RT–
PCR amplified cSNP (c.2109C>T) in OPA1, they found that
mutant transcript levels reduced between 1.25- and 2.5-fold
and varied among premature termination codons containing
mutations [24].
In conclusion, we described 2 novel mutations of the
OPA1 gene in Chinese ADOA families. Our findings expand
the spectrum of OPA1 gene mutation and provided useful
genetic consultation and genetic diagnosis for the families.
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